Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed)
ID: 337854Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/337854

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-111.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed)." This grant aims to support translational research that enhances the validation of innovative therapeutic leads, particularly in the areas of diabetes, kidney, and digestive diseases, which are relevant to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Successful proposals should present novel therapeutic approaches, including small molecules and non-viral biologics, and demonstrate significant potential improvements over existing treatments. The NIH anticipates awarding 3-4 grants annually, with funding amounts ranging from $250,000 to $300,000 for a maximum project period of five years. Interested applicants are encouraged to reach out to NIH scientific contacts for programmatic discussions prior to submission, and the application deadline is January 7, 2025. For more information, applicants can refer to the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-111.html or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-111.html
    The National Institutes of Health (NIH) is offering a funding opportunity focused on early-stage preclinical validation of therapeutic leads relevant to diabetes, kidney, and digestive diseases through the R01 Research Project Grant. This program, re-seeking proposals previously issued under PAR-22-111, aims to stimulate research that enhances the validation of novel therapeutics not prioritized by the commercial sector. Eligible applications should present innovative therapeutic leads, which include small molecules and non-viral biologics, and provide evidence of potential improvements over existing treatments. Successful projects must significantly contribute data supporting therapeutic validity to facilitate later funding opportunities for advanced development. The NIH anticipates awarding 3-4 grants annually, each ranging from $250,000 to $300,000, over a maximum project period of five years. Proposals should comply with strict application instructions and showcase a thorough understanding of the competitive landscape and therapeutic relevance to NIH missions. Interested applicants are encouraged to contact NIH scientific contacts for programmatic discussions before submission.
    Similar Opportunities
    Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for small Research Project Grants (R01s) aimed at clinical trials focused on diseases under the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This initiative encourages the submission of pilot and feasibility clinical trials that will provide foundational data for larger, definitive trials intended to improve the prevention and treatment of various health conditions, without the requirement of preliminary efficacy data. The program supports innovative research ideas and emphasizes equitable recruitment from diverse populations, with a maximum grant duration of three years and funding up to $200,000 per year. Interested applicants can find more information and submit their applications by May 7, 2026, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    High Impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Impact, Interdisciplinary Science in NIDDK Research Areas" (PAR-25-277) aimed at supporting innovative research that addresses critical knowledge gaps in diabetes, digestive, and kidney diseases. This grant program encourages interdisciplinary approaches to foster discovery-based science and develop transformative technologies that can significantly impact the broader scientific community. Eligible applicants include a wide range of organizations, such as higher education institutions and nonprofits, with proposals accepted for projects lasting up to five years. Interested parties should ensure compliance with application guidelines and submit their proposals by the deadline of October 15, 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-277.html.
    NIDDK Education Program Grants (R25 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering Research Education Program Grants (R25) to enhance training in biomedical, behavioral, and clinical research. This funding opportunity aims to support educational activities that develop research skills and provide hands-on experiences in areas critical to NIDDK, including diabetes, digestive diseases, and obesity. Eligible applicants include a wide range of organizations such as higher education institutions, non-profits, and local governments, with a funding limit of $100,000 per year for up to five years. The application deadline is January 30, 2024, and interested parties can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the program's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-074.html.
    NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed) to support pioneering biomedical research focused on critical scientific challenges related to diabetes, digestive diseases, and kidney diseases. This grant aims to fund individual scientists proposing innovative and high-impact studies that diverge from their existing research, encouraging bold ideas and unconventional hypotheses within the domains of the Division of Diabetes, Endocrinology and Metabolic Diseases and the Division of Digestive Diseases and Nutrition. The award has a budget ceiling of $500,000 per year for a maximum project period of five years, with a total funding commitment of $4.8 million for FY 2026 to support up to six awards. Interested applicants must adhere to NIH registration requirements and submit their proposals by July 18, 2025, with further inquiries directed to grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting investigator-initiated, high-risk clinical trials that involve multiple clinical centers. Applicants must propose hypothesis-driven studies that focus on diseases relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), with an emphasis on enhancing diverse perspectives in research. This funding opportunity is crucial for advancing therapeutic studies that can significantly improve clinical practices and public health outcomes. Interested applicants should note that the application period opens on January 5, 2024, with a closing date of November 5, 2026, and are encouraged to consult with NIDDK staff prior to submission. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)" to stimulate research aligned with the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This initiative aims to support research on HIV-related comorbidities, gastrointestinal diseases, and metabolic disorders associated with HIV, encouraging applications from a diverse range of organizations, including higher education institutions and non-profits. With an estimated funding of $2 million for fiscal year 2025, the NIH plans to support 3 to 5 selected projects over a maximum project period of five years, with applications undergoing a rigorous peer review process. Interested applicants can find more information and submit their proposals through Grants.gov, with a submission deadline of January 7, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting high-risk observational studies related to diabetes, digestive, kidney, and metabolic diseases. Applicants must complete all planning activities prior to submission, as these cannot be included in the U01 application, and a Plan for Enhancing Diverse Perspectives (PEDP) is mandatory for consideration. This funding opportunity is crucial for advancing clinical research and addressing health disparities, particularly by encouraging collaboration with underrepresented communities. Interested applicants should note that the application deadline is February 5, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity for high-risk multi-center clinical study implementation planning via Cooperative Agreements (U34). This initiative aims to support the early peer review of proposed clinical studies, assess study designs, and develop essential documentation, including operational manuals, focusing on diseases relevant to NIDDK's mission. The program emphasizes health equity and inclusivity, requiring a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Interested applicants can apply for up to $225,000 per year for a maximum of two years, with the application submission period opening on September 9, 2024, and the closing date set for June 10, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    Limited Competition: Small Grant Program for NIDDK K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), has announced a Limited Competition Small Grant Program aimed at supporting current K01, K08, K23, and K25 award recipients. This program is designed to facilitate the transition of these early-career researchers to fully independent investigator status by providing funding for small, self-contained research projects, with grants offering up to $75,000 in direct costs per year for a maximum project period of two years. The initiative encourages applicants to demonstrate their growing independence and ability to secure future funding, particularly for R01 applications, while adhering to NIH policies regarding human subjects and clinical trials. Interested applicants must submit their proposals by September 7, 2025, and can find additional information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 exploratory research grant titled "Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics." This grant aims to support preclinical and patient-based studies that investigate how incretin mimetics, specifically GLP-1 and GIP-1 receptor agonists, influence cancer risk, particularly in relation to obesity-related cancers such as thyroid and prostate cancers. The funding, which amounts to a maximum of $275,000 over two years, is intended for projects that do not involve clinical trials, with applications opening in January 2024 and a submission deadline of January 7, 2027. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.